tiprankstipranks
Blurbs

Analysts Conflicted on These Healthcare Names: Calithera Bio (CALA), Beauty Health (SKIN) and Entrada Therapeutics Inc (TRDA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Calithera Bio (CALAResearch Report), Beauty Health (SKINResearch Report) and Entrada Therapeutics Inc (TRDAResearch Report).

Calithera Bio (CALA)

SVB Securities analyst Jonathan Chang maintained a Buy rating on Calithera Bio today and set a price target of $18.00. The company’s shares closed last Tuesday at $3.96, close to its 52-week low of $2.30.

According to TipRanks.com, Chang ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.3% and a 33.5% success rate. Chang covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Karyopharm Therapeutics, and Revolution Medicines.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Calithera Bio.

See Insiders’ Hot Stocks on TipRanks >>

Beauty Health (SKIN)

In a report released today, Amit Hazan from Goldman Sachs maintained a Buy rating on Beauty Health, with a price target of $22.00. The company’s shares closed last Tuesday at $13.52.

According to TipRanks.com, Hazan is a 4-star analyst with an average return of 6.4% and a 55.0% success rate. Hazan covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Bausch + Lomb Corporation, and Baxter International.

Beauty Health has an analyst consensus of Strong Buy, with a price target consensus of $22.20, which is a 62.6% upside from current levels. In a report issued on August 10, Piper Sandler also maintained a Buy rating on the stock with a $20.00 price target.

Entrada Therapeutics Inc (TRDA)

Goldman Sachs analyst Chris Shibutani maintained a Hold rating on Entrada Therapeutics Inc today and set a price target of $13.00. The company’s shares closed last Tuesday at $12.50.

According to TipRanks.com, Shibutani is a 5-star analyst with an average return of 23.2% and a 48.5% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Arcutis Biotherapeutics, and Prometheus Biosciences.

Entrada Therapeutics Inc has an analyst consensus of Hold, with a price target consensus of $13.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CALA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More